Tom knows that we need to build on these successes by increasing the number of drugs Medicare can negotiate and passing on the cost savings to people with private insurance as well.
Suozzi will build on Medicare drug-price reforms by increasing the number of drugs Medicare can negotiate and extending savings to people with private insurance.
Occurrences
Lower the Cost of Living, Repeal the SALT Cap, and Further Reduce Prescription Drug Prices
Evidence
legacy_unverified · Source version not recorded · locator unknown
Tom knows that we need to build on these successes by increasing the number of drugs Medicare can negotiate and passing on the cost savings to people with private insurance as well.
legacy_unverified · Source version not recorded · locator unknown
To expand the drug price negotiation program under title XI of the Social Security Act and repeal certain changes to the program made by Public Law 119–21, to apply prescription drug inflation rebates under the Medicare program to drugs furnished in the commercial market, and to establish out-of-pocket limits on expenditures for prescription drugs under private health insurance.
legacy_unverified · Source version not recorded · locator unknown
In August 2022, President Biden signed the Inflation Reduction Act of 2022 (P.L. 117-169) into law. For the first time, the law provides Medicare the ability to directly negotiate the prices of certain high expenditure, single source drugs without generic or biosimilar competition. CMS selected ten drugs covered under Medicare Part D for the first cycle of negotiations for initial price applicability year 2026.
legacy_unverified · Source version not recorded · locator unknown
This bill expands the Medicare Drug Price Negotiation Program to include additional drugs and drugs that are covered under private insurance. It also extends certain rebate requirements for covered drugs under Medicare to drugs that are covered under private insurance.
legacy_unverified · Source version not recorded · locator unknown
The Congressional Record shows Rep. Suozzi spoke in support of adding the Lowering Drug Costs for American Families Act to the House rules package, describing it as expanding Medicare negotiated drug prices to the private sector. The same record shows the previous question was ordered 216-210 on Roll No. 3, with Suozzi listed among the nays, preventing the proposed amendment path from advancing.
legacy_unverified · Source version not recorded · locator unknown
Congress.gov lists H.R. 6166 as sponsored by Rep. Frank Pallone, referred on November 20, 2025 to House Energy and Commerce, Ways and Means, and Education and Workforce, and still at the Introduced status. The cosponsor page lists 47 current cosponsors and does not list Rep. Suozzi.
Assessments
The promised outcome has not been enacted: the matching federal legislation, H.R. 6166, remains at introduced/referred status rather than law, and existing IRA Medicare negotiation implementation does not extend negotiated savings to private insurance or further increase negotiation authority as promised. Suozzi did take concrete same-term action by speaking on the House floor in support of adding the Lowering Drug Costs for American Families Act to the rules package, but that procedural path failed and did not deliver the policy.
The promised outcome was to expand Medicare drug negotiation beyond existing IRA reforms and extend savings to people with private insurance. Existing CMS implementation covers the prior IRA Medicare-only negotiation framework and does not deliver the private-insurance extension. Later bills matching the promise, including H.R. 4895 in the 118th Congress and H.R. 6166 in the 119th Congress, remained introduced or referred and did not become law. Available Congress.gov cosponsor records do not show Suozzi sponsoring or cosponsoring those bills, so there is not enough candidate-specific legislative effort for an effort badge.
The promised outcome required both expanding the number of drugs subject to Medicare negotiation and extending those savings to people with private insurance. The Inflation Reduction Act created and began Medicare negotiation, but that was baseline law and did not extend negotiated savings to private insurance. Later bills aimed at this broader policy were introduced but not enacted, and the provided evidence does not establish that Suozzi personally made a serious legislative or executive attempt sufficient for an effort badge. Therefore the promised outcome has not been delivered.